Frameworks for Progress The Michael J. Fox Foundation for Parkinson’s Research 2016 Annual Report The Michael J. Fox Foundation Contents is dedicated to finding a cure for Parkinson’s disease through an 2 A Note from Michael aggressively funded research 3 An Update from the CEO and the Co-Founder 6 2016 in Photos agenda and to ensuring the 8 2016 Donor Listing development of improved 11 Planned Giving therapies for those living with 13 Industry Partners 18 Corporate and Matching Gifts Parkinson’s today. 28 Tributees 44 Recurring Gifts 46 Team Fox 58 2016 Financial Highlights 64 Credits 65 Boards and Councils 2016 Annual Report 3 The Michael J. Fox Foundation Contents is dedicated to finding a cure for Parkinson’s disease through an 2 A Note from Michael aggressively funded research 3 An Update from the CEO and the Co-Founder 6 2016 in Photos agenda and to ensuring the 8 2016 Donor Listing development of improved 11 Planned Giving therapies for those living with 13 Industry Partners 18 Corporate and Matching Gifts Parkinson’s today. 28 Tributees 44 Recurring Gifts 46 Team Fox 58 2016 Financial Highlights 64 Credits 65 Boards and Councils A Note from An Update from the CEO Michael and the Co-Founder Dear Friend, Each year, we are honored to share how your unflagging determination and sheer generosity have fortified our mission to do whatever it takes to drive research. As a Todd Sherer, PhD Deborah W. Brooks Chief Executive Officer Co-Founder and Executive year full of new endeavors and tremendous Vice Chairman growth, 2016 was no exception. We still have much to do, but your dedication is building a better future The question most frequently asked of for the millions living with Parkinson’s. The Michael J. Fox Foundation (MJFF) is: “How I’m so grateful for your friendship. close are we to a cure for Parkinson’s disease?” Together, I have no doubt that we will With nearly $750 million in Parkinson’s disease (PD) cure Parkinson’s. research funded to date, the simplest answer is: closer than ever. Today’s PD drug development pipeline demonstrates a richness and vibrancy we could only dream of a few short years ago. But nothing is simple, least of all and it is fair to say that the state of brain research, and every promising Parkinson’s science as a whole has step forward reveals complex new meaningfully advanced. Multiple challenges for our problem-solving. scientific breakthroughs, promising As you’ll read in this report, our new leads and powerful information community increasingly is called on technology have combined to set the not just to provide funding for the stage for better disease understanding most important research projects from the patients themselves. in the Parkinson’s space, but also to Our on-staff PhD-trained engage with MJFF as we lead and neuroscientists paired with business- coordinate wide-ranging initiatives trained project managers are that help advance the entire field — identifying, vetting and advancing frameworks, as it were, for progress. the most promising ideas in In the Foundation’s short history, Parkinson’s research, building a Parkinson’s drug development has portfolio that includes investigations experienced a metamorphosis, of over 1,000 drug targets to date. 2 The Michael J. Fox Foundation 2016 Annual Report 5 A Note from An Update from the CEO Michael and the Co-Founder Dear Friend, Each year, we are honored to share how your unflagging determination and sheer generosity have fortified our mission to do whatever it takes to drive research. As a Todd Sherer, PhD Deborah W. Brooks Chief Executive Officer Co-Founder and Executive year full of new endeavors and tremendous Vice Chairman growth, 2016 was no exception. We still have much to do, but your dedication is building a better future The question most frequently asked of for the millions living with Parkinson’s. The Michael J. Fox Foundation (MJFF) is: “How I’m so grateful for your friendship. close are we to a cure for Parkinson’s disease?” Together, I have no doubt that we will With nearly $750 million in Parkinson’s disease (PD) cure Parkinson’s. research funded to date, the simplest answer is: closer than ever. Today’s PD drug development pipeline demonstrates a richness and vibrancy we could only dream of a few short years ago. But nothing is simple, least of all and it is fair to say that the state of brain research, and every promising Parkinson’s science as a whole has step forward reveals complex new meaningfully advanced. Multiple challenges for our problem-solving. scientific breakthroughs, promising As you’ll read in this report, our new leads and powerful information community increasingly is called on technology have combined to set the not just to provide funding for the stage for better disease understanding most important research projects from the patients themselves. in the Parkinson’s space, but also to Our on-staff PhD-trained engage with MJFF as we lead and neuroscientists paired with business- coordinate wide-ranging initiatives trained project managers are that help advance the entire field — identifying, vetting and advancing frameworks, as it were, for progress. the most promising ideas in In the Foundation’s short history, Parkinson’s research, building a Parkinson’s drug development has portfolio that includes investigations experienced a metamorphosis, of over 1,000 drug targets to date. 4 The Michael J. Fox Foundation 2016 Annual Report 3 advocating for public policy or — Initiative (PPMI), our landmark study like those honored in this report launched in 2010 to jump-start the — providing significant financial search for Parkinson’s biomarkers “The Michael J. Fox support for our work, the Parkinson’s — disease indicators that are critical community is more committed than missing links in the search for next- ever before to getting involved. That’s generation PD treatments. And the why we’ve restructured our staff to study has expanded beyond the Foundation, almost add a Community Engagement team, original cohort to look at genetics to our newest framework dedicated track the disease process at the earliest to helping patients and their loved stages of illness. ones navigate the broad range of And because Parkinson’s public singlehandedly, has multi-faceted opportunities to play a policy concerns have evolved personal role in our mission. with the landscape of Parkinson’s Any truly patient-centric program therapeutic development, in 2016, catapulted… research.” starts from the proposition that the Foundation announced its patients are the true experts on integration of the former Parkinson’s living with disease. Today, thousands Action Network and launch of a of patients and their loved ones robust policy program. Our work —BioWorld Today, October 2016 have enrolled in Fox Insight in three priority areas — federal (foxinsight.org), our online clinical research funding, drug regulation study, helping researchers gain a and approval, and health care delivery holistic understanding of PD and and reimbursement — is bringing the revolutionizing Parkinson’s research passion and commitment of the PD by contributing PROs (patient- community to bear on articulating reported outcomes) on disease course, and advancing public policy that symptom progression and treatment stands to affect millions of patients outcomes, among other vital data. and families. These participants are part of a Drug development is a high- growing community of citizen risk business, and sometimes a scientists. More than 65,000 have discouraging one. At The Michael J. When a promising target framework for progress — is working. registered with our smart-matching Fox Foundation, we believe we are demonstrates sustained potential Today, several symptomatic therapies tool Fox Trial Finder (foxtrialfinder. building the framework to tilt the to benefit people with Parkinson’s, for motor and non-motor symptoms org), which in 2016 expanded to odds in favor of success — identifying we move quickly to coordinate an are in Phase III clinical testing, with include atypical parkinsonisms and accelerating the research with entire field of activity in support of one or more expected to file for FDA multiple system atrophy, Lewy body potential to transform every life its continued forward movement. approval within the calendar year; dementia and others. More than 1,000 touched by Parkinson’s. We can’t do We tackle roadblocks head-on, compare that to the PD landscape as have enrolled in the MJFF-sponsored it without you. Thank you for sharing providing researchers with resources recently as 2011, when not a single Parkinson’s Progression Markers our vision. to generate data and build the case for Parkinson’s therapy was being tested high-impact ideas, and sophisticated in late-stage clinical trials. And tools that can help science move there are no fewer than nine disease- through testing and toward modifying therapies advancing regulatory approval faster. This through clinical testing that could includes characterizing molecular slow, stop or even reverse progression biology, developing strategies to of PD — something no current objectively measure pathology and treatment is proven to do. With gratitude, treatment effects, assembling patient This progress is set against the cohorts, and creating technology backdrop of a new era of patient infrastructure to gather and analyze power, with a seismic opportunity “big data” for use by researchers in for patients to partner with scientists MJFF-led and independent studies. to influence research design and Todd Sherer, PhD Deborah W. Brooks And, it’s clear that our Foundation’s outcomes. Whether volunteering for Chief Executive Officer Co-Founder and Executive “de-risking” method — a critical traditional or virtual clinical trials, Vice Chairman 4 The Michael J. Fox Foundation 2016 Annual Report 7 advocating for public policy or — Initiative (PPMI), our landmark study like those honored in this report launched in 2010 to jump-start the — providing significant financial search for Parkinson’s biomarkers “The Michael J.